Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Q901 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Dose escalation (Q901) | EXPERIMENTAL | - |
| Q901 Single-Agent Expansion Cohorts | EXPERIMENTAL | - |
| Q901 + KEYTRUDA® (pembrolizumab) Cohorts | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Q901 | DRUG | The study drug Q901 will be administered by IV infusion over a 30-minute period using a QW dosing schedule for 4 weeks, followed by a Q2W interval dosing schedule thereafter |
| KEYTRUDA® (pembrolizumab) | DRUG | KEYTRUDA® (pembrolizumab) will be administered Q6W |
Inclusion Criteria: * Participants with histologically or cytologically confirmed advanced or metastatic ovarian, CRPC, HR+ HER2- breast, endometrial, colorectal, small-cell lung, or pancreatic cancer, who have progressed following standard-of-care therapy or for whom there is no standard therapy t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
Q901 is an investigational small molecule being studied for the treatment of advanced and metastatic cancer. It is currently in Phase 1 clinical development, with a trial enrolling patients with advanced solid tumors. The drug is being evaluated as a potential therapy for these conditions, though it is not yet approved.
Q901 is a highly selective CDK7 inhibitor. CDK7 is a cyclin-dependent kinase involved in cell cycle regulation and transcription. By inhibiting CDK7, Q901 aims to disrupt cancer cell proliferation. This targeted mechanism is being investigated in a Phase 1 trial for advanced solid tumors.
Q901 is being developed by Merck & Company, Inc., a global pharmaceutical company. Merck is conducting clinical trials to evaluate the safety and efficacy of Q901 in patients with advanced cancer. The company is listed on the stock exchange under the ticker symbol MRK.
Q901 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial is currently recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
Q901 is being studied in a Phase 1 clinical trial with the identifier NCT05394103. The trial is titled 'Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors' and is recruiting 130 participants in the United States and South Korea. The study is open to adults aged 18 and older.
Q901 is a specific investigational CDK7 inhibitor developed by Merck. While it shares a target with other CDK7 inhibitors, Q901 is a distinct compound with its own chemical structure and clinical development program. No alternative names for Q901 have been reported.